Distributor Orders Nexstim NBS System 5 for European Hospital

Press release, Helsinki, 10 June 2024 at 9 AM (EEST)

Distributor Orders Nexstim NBS System 5 for European Hospital

Advertisement

Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) has received an order for an NBS System 5 from a distributor for a European hospital.

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning. The specific system ordered can also be used for therapy, where the NBS System 5 is CE-marked for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: “In addition to strategic partnerships and other business activity we are actively engaging in, system sales remain an important aspect of our profitable growth journey. We have seen continued demand for the combined diagnostics and therapeutics options of our NBS System 5.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
[email protected]

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

Attachment

  • Nexstim Plc_Press release_EU order_10062024_FINAL

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.